368 related articles for article (PubMed ID: 8254663)
41. Identification of limiting steps for efficient trans-activation of HIV-1 promoter by Tat in Saccharomyces cerevisiae.
Daviet L; Bois F; Battisti PL; Gatignol A
J Biol Chem; 1998 Oct; 273(43):28219-28. PubMed ID: 9774443
[TBL] [Abstract][Full Text] [Related]
42. The leucine domain of the visna virus Tat protein mediates targeting to an AP-1 site in the viral long terminal repeat.
Carruth LM; Morse BA; Clements JE
J Virol; 1996 Jul; 70(7):4338-44. PubMed ID: 8676456
[TBL] [Abstract][Full Text] [Related]
43. Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors.
Gatignol A; Duarte M; Daviet L; Chang YN; Jeang KT
Gene Expr; 1996; 5(4-5):217-28. PubMed ID: 8723388
[TBL] [Abstract][Full Text] [Related]
44. Requirement of the human immunodeficiency virus type 1 env gene sequence for TAR-independent trans activation by Tat from the major immediate-early promoter of murine cytomegalovirus.
Kim YS
Biochem Biophys Res Commun; 1994 Sep; 203(2):1152-9. PubMed ID: 8093034
[TBL] [Abstract][Full Text] [Related]
45. Chimeras of herpes simplex viral VP16 and jun are oncogenic.
Schuur ER; Parker EJ; Vogt PK
Cell Growth Differ; 1993 Sep; 4(9):761-8. PubMed ID: 8241024
[TBL] [Abstract][Full Text] [Related]
46. Kinetics of HIV-1 long terminal repeat trans-activation. Use of intragenic ribozyme to assess rate-limiting steps.
Jeang KT; Berkhout B
J Biol Chem; 1992 Sep; 267(25):17891-9. PubMed ID: 1517225
[TBL] [Abstract][Full Text] [Related]
47. Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site.
Schafer SL; Vlach J; Pitha PM
J Virol; 1996 Oct; 70(10):6937-46. PubMed ID: 8794337
[TBL] [Abstract][Full Text] [Related]
48. Weak transcriptional activation is sufficient for transformation by v-Myb.
Engelke U; Whittaker L; Lipsick JS
Virology; 1995 Apr; 208(2):467-77. PubMed ID: 7747419
[TBL] [Abstract][Full Text] [Related]
49. Synergistic activation of the human immunodeficiency virus type 1 promoter by the viral Tat protein and cellular transcription factor Sp1.
Kamine J; Chinnadurai G
J Virol; 1992 Jun; 66(6):3932-6. PubMed ID: 1583736
[TBL] [Abstract][Full Text] [Related]
50. Human immunodeficiency virus type 1 Tat binding protein-1 is a transcriptional coactivator specific for TR.
Ishizuka T; Satoh T; Monden T; Shibusawa N; Hashida T; Yamada M; Mori M
Mol Endocrinol; 2001 Aug; 15(8):1329-43. PubMed ID: 11463857
[TBL] [Abstract][Full Text] [Related]
51. Transactivation of heterologous promoters by HIV-1 tat.
Han P; Brown R; Barsoum J
Nucleic Acids Res; 1991 Dec; 19(25):7225-9. PubMed ID: 1662814
[TBL] [Abstract][Full Text] [Related]
52. The retinoblastoma susceptibility gene product regulates Myc-mediated transcription.
Adnane J; Robbins PD
Oncogene; 1995 Jan; 10(2):381-7. PubMed ID: 7838535
[TBL] [Abstract][Full Text] [Related]
53. Activation of a heterologous promoter by human immunodeficiency virus type 1 Tat requires Sp1 and is distinct from the mode of activation by acidic transcriptional activators.
Kamine J; Subramanian T; Chinnadurai G
J Virol; 1993 Nov; 67(11):6828-34. PubMed ID: 8411386
[TBL] [Abstract][Full Text] [Related]
54. The type 1 human immunodeficiency virus Tat binding protein is a transcriptional activator belonging to an additional family of evolutionarily conserved genes.
Ohana B; Moore PA; Ruben SM; Southgate CD; Green MR; Rosen CA
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):138-42. PubMed ID: 8419915
[TBL] [Abstract][Full Text] [Related]
55. Delineating minimal protein domains and promoter elements for transcriptional activation by lentivirus Tat proteins.
Southgate CD; Green MR
J Virol; 1995 Apr; 69(4):2605-10. PubMed ID: 7884911
[TBL] [Abstract][Full Text] [Related]
56. Second-site long terminal repeat (LTR) revertants of replication-defective human immunodeficiency virus: effects of revertant TATA box motifs on virus infectivity, LTR-directed expression, in vitro RNA synthesis, and binding of basal transcription factors TFIID and TFIIA.
Kashanchi F; Shibata R; Ross EK; Brady JN; Martin MA
J Virol; 1994 May; 68(5):3298-307. PubMed ID: 8151790
[TBL] [Abstract][Full Text] [Related]
57. Doxorubicin inhibits Tat-dependent transactivation of HIV type 1 LTR.
Jeyaseelan R; Kurabayashi M; Kedes L
AIDS Res Hum Retroviruses; 1996 May; 12(7):569-76. PubMed ID: 8743082
[TBL] [Abstract][Full Text] [Related]
58. GAL4-VP16 is an unusually potent transcriptional activator.
Sadowski I; Ma J; Triezenberg S; Ptashne M
Nature; 1988 Oct; 335(6190):563-4. PubMed ID: 3047590
[TBL] [Abstract][Full Text] [Related]
59. Three functional classes of transcriptional activation domain.
Blau J; Xiao H; McCracken S; O'Hare P; Greenblatt J; Bentley D
Mol Cell Biol; 1996 May; 16(5):2044-55. PubMed ID: 8628270
[TBL] [Abstract][Full Text] [Related]
60. Tat-induced lesions in transgenic mice do not correlate with the HIV-1 LTR transactivation.
Fergelot P; Molina T; Blanchet P; Grimber G; Duquenne O; Couton D; Zider A; Briand P; Cavard C
C R Acad Sci III; 1995 Mar; 318(3):329-37. PubMed ID: 7788501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
